The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer.
Yelena Yuriy Janjigian
Research Funding - Boehringer Ingelheim
David Ilson
No relevant relationships to disclose
David Paul Kelsen
No relevant relationships to disclose
Mark Schattner
No relevant relationships to disclose
Adriana Heguy
No relevant relationships to disclose
Efsevia Vakiani
No relevant relationships to disclose